ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C
- PMID: 20173735
- DOI: 10.1038/nature08825
ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C
Abstract
Chronic infection with the hepatitis C virus (HCV) affects 170 million people worldwide and is an important cause of liver-related morbidity and mortality. The standard of care therapy combines pegylated interferon (pegIFN) alpha and ribavirin (RBV), and is associated with a range of treatment-limiting adverse effects. One of the most important of these is RBV-induced haemolytic anaemia, which affects most patients and is severe enough to require dose modification in up to 15% of patients. Here we show that genetic variants leading to inosine triphosphatase deficiency, a condition not thought to be clinically important, protect against haemolytic anaemia in hepatitis-C-infected patients receiving RBV.
Comment in
-
Personalized medicine in hepatitis C: from genome-wide association studies to clinical practice.Hepatology. 2010 Jun;51(6):2223-5. doi: 10.1002/hep.23738. Hepatology. 2010. PMID: 20513008 No abstract available.
-
Unraveling the genetic predisposition of ribavirin-induced anaemia.J Hepatol. 2010 Nov;53(5):971-3. doi: 10.1016/j.jhep.2010.06.007. Epub 2010 Jul 21. J Hepatol. 2010. PMID: 20797805 No abstract available.
Similar articles
-
Relationship between polymorphisms of the inosine triphosphatase gene and anaemia or outcome after treatment with pegylated interferon and ribavirin.Antivir Ther. 2011;16(5):685-94. doi: 10.3851/IMP1796. Antivir Ther. 2011. PMID: 21817190
-
ITPA gene polymorphism (94C>A) effects on ribavirin-induced anemia during therapy in Egyptian patients with chronic hepatitis C.J Med Virol. 2017 Oct;89(10):1823-1829. doi: 10.1002/jmv.24844. Epub 2017 May 29. J Med Virol. 2017. PMID: 28480960
-
[Genome-wide association study on and the clinical application to chronic hepatitis C].Uirusu. 2011 Jun;61(1):15-24. doi: 10.2222/jsv.61.15. Uirusu. 2011. PMID: 21972552 Review. Japanese.
-
Relationship between ITPA polymorphisms and hemolytic anemia in HCV-infected patients after ribavirin-based therapy: a meta-analysis.J Transl Med. 2015 Oct 6;13:320. doi: 10.1186/s12967-015-0682-y. J Transl Med. 2015. PMID: 26438033 Free PMC article.
-
Pharmacogenetics of ribavirin-induced anemia in HCV patients.Pharmacogenomics. 2016 Jun;17(8):925-41. doi: 10.2217/pgs.16.22. Epub 2016 Jun 1. Pharmacogenomics. 2016. PMID: 27248282 Review.
Cited by
-
Association of ITPA gene variation and serum ribavirin concentration with a decline in blood cell concentrations during pegylated interferon-alpha plus ribavirin therapy for chronic hepatitis C.Hepatol Int. 2013 Mar;7(1):153-61. doi: 10.1007/s12072-012-9363-6. Epub 2012 Mar 21. Hepatol Int. 2013. PMID: 26201629
-
The impact of an inosine triphosphate pyrophosphatase genotype on bilirubin increase in chronic hepatitis C patients treated with simeprevir, pegylated interferon plus ribavirin.J Gastroenterol. 2016 Mar;51(3):252-9. doi: 10.1007/s00535-015-1105-9. Epub 2015 Jul 30. J Gastroenterol. 2016. PMID: 26223482 Clinical Trial.
-
A disease spectrum for ITPA variation: advances in biochemical and clinical research.J Biomed Sci. 2016 Oct 22;23(1):73. doi: 10.1186/s12929-016-0291-y. J Biomed Sci. 2016. PMID: 27770805 Free PMC article. Review.
-
New and Evolving Management Paradigms for Hepatitis C after Liver Transplantation.Curr Hepat Rep. 2011 Sep;10(3):179-185. doi: 10.1007/s11901-011-0103-5. Curr Hepat Rep. 2011. PMID: 22448143 Free PMC article.
-
Deoxyinosine triphosphate induces MLH1/PMS2- and p53-dependent cell growth arrest and DNA instability in mammalian cells.Sci Rep. 2016 Sep 13;6:32849. doi: 10.1038/srep32849. Sci Rep. 2016. PMID: 27618981 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Miscellaneous